Charles Explorer logo
🇬🇧

Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer

Publication at First Faculty of Medicine |
2015

Abstract

Pancreatic cancer is the fourth leading cause of cancer death in the developed world(1). Both inherited high-penetrance mutations in BRCA2 (ref. 2), ATM(3), PALB2 (ref. 4), BRCA1 (ref. 5), STK11 (ref. 6), CDKN2A(7) and mismatch-repair genes(8) and low-penetrance loci are associated with increased risk(9-12).

To identify new risk loci, we performed a genome-wide association study on 9,925 pancreatic cancer cases and 11,569 controls, including 4,164 newly genotyped cases and 3,792 controls in 9 studies from North America, Central Europe and Australia. We identified three newly associated regions: 17q25.1 (LINC00673, rs11655237, odds ratio (OR) = 1.26, 95% confidence interval (CI) = 1.19-1.34, P = 1.42 x 10(-14)), 7p13 (SUGCT, rs17688601, OR = 0.88, 95% CI = 0.84-0.92, P = 1.41 x 10(-8)) and 3q29 (TP63, rs9854771, OR = 0.89, 95% CI = 0.85-0.93, P = 2.35 x 10(-8)).

We detected significant association at 2p13.3 (ETAA1, rs1486134, OR = 1.14, 95% CI = 1.09-1.19, P = 3.36 x 10(-9)), a region with previous suggestive evidence in Han Chinese(12). We replicated previously reported associations at 9q34.2 (ABO)(9), 13q22.1 (KLF5)(10), 5p15.33 (TERT and CLPTM1)(10,11), 13q12.2 (PDX1)(11), 1q32.1 (NR5A2)(10), 7q32.3 (LINC-PINT)(11), 16q23.1 (BCAR1)(11) and 22q12.1 (ZNRF3)(11).

Our study identifies new loci associated with pancreatic cancer risk.